GTSM:4147

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

TaiMed Biologics Inc., a biotechnology company, develops health-care products. More Details

Rewards

Earnings are forecast to grow 139.24% per year

Risk Analysis

No risks detected for 4147 from our risk checks.


Snowflake Analysis

Exceptional growth potential with excellent balance sheet.

Share Price & News

How has TaiMed Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4147 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4147's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-2.4%

4147

-0.3%

TW Biotechs

2.0%

TW Market


1 Year Return

-22.0%

4147

22.9%

TW Biotechs

31.2%

TW Market

Return vs Industry: 4147 underperformed the TW Biotechs industry which returned 22.9% over the past year.

Return vs Market: 4147 underperformed the TW Market which returned 31.2% over the past year.


Shareholder returns

4147IndustryMarket
7 Day-2.4%-0.3%2.0%
30 Day-13.8%-6.1%10.6%
90 Day-15.0%-0.3%22.8%
1 Year-22.0%-22.0%23.3%22.9%35.8%31.2%
3 Year-63.4%-63.4%-18.1%-19.5%58.3%40.5%
5 Year-68.0%-68.0%-51.3%-51.7%133.0%92.1%

Long-Term Price Volatility Vs. Market

How volatile is TaiMed Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TaiMed Biologics undervalued compared to its fair value and its price relative to the market?

5.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 4147 (NT$73) is trading above our estimate of fair value (NT$31.97)

Significantly Below Fair Value: 4147 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4147 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 4147 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4147's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4147 is overvalued based on its PB Ratio (5.2x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is TaiMed Biologics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

139.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4147 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).

Earnings vs Market: 4147 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 4147's is expected to become profitable in the next 3 years.

Revenue vs Market: 4147's revenue (80% per year) is forecast to grow faster than the TW market (11.2% per year).

High Growth Revenue: 4147's revenue (80% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4147's Return on Equity is forecast to be high in 3 years time (26.9%)


Next Steps

Past Performance

How has TaiMed Biologics performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4147 is currently unprofitable.

Growing Profit Margin: 4147 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4147 is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare 4147's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4147 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 4147 has a negative Return on Equity (-4.93%), as it is currently unprofitable.


Next Steps

Financial Health

How is TaiMed Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: 4147's short term assets (NT$2.8B) exceed its short term liabilities (NT$375.6M).

Long Term Liabilities: 4147's short term assets (NT$2.8B) exceed its long term liabilities (NT$1.3B).


Debt to Equity History and Analysis

Debt Level: 4147's debt to equity ratio (15.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 4147's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4147 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 4147 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25.9% each year


Next Steps

Dividend

What is TaiMed Biologics's current dividend yield, its reliability and sustainability?

2.99%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4147's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4147's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4147's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4147's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4147's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average board tenure


CEO

James Chang

no data

Tenure

James Chang, Ph.D serves as the Chief Executive Officer, President and Director of TaiMed Biologics, Inc. James Chang served as Senior Director of Allergan Pharmaceuticals, Irvine, CA. James Chang holds P...


Board Members

NamePositionTenureCompensationOwnership
James Chang
CEO, President & Directorno datano datano data
Ta-mon Tseng
Director2yrsno datano data
Chi-Chuan Chen
Directorno datano datano data
Lu-Ping Chow
Chairman of the Board1yrno datano data
Hsiao-Ling Shen
Supervisorno datano datano data
Grace Lee
Supervisorno datano datano data
Chien-Kun Lin
Director1yrno datano data
Young Tai-Horng
Chairman of the Board1yrno datano data
Lin Gwo-Fong
Independent Director0.58yrno datano data

1.0yrs

Average Tenure

Experienced Board: 4147's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TaiMed Biologics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TaiMed Biologics Inc.
  • Ticker: 4147
  • Exchange: GTSM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$18.488b
  • Shares outstanding: 252.22m
  • Website: https://www.taimedbiologics.com

Location

  • TaiMed Biologics Inc.
  • No. 607, Ruiguang Road
  • 3rd Floor
  • Taipei
  • 11492
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4147GTSM (Taipei Exchange)YesCommon StockTWTWDJun 2010

Biography

TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company develops and markets TMB-355, a humanized monoclonal antibody intravenous infusion for the treatment of HIV-1 infe...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 17:14
End of Day Share Price2021/01/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.